Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
!!Search content at Johns Hopkins University
Home
Profiles
Research units
Research output
Clinical effects and toxicity of interleukin‐2 in patients with cancer
Michael T. Lotze
, Yvedt L. Matory
, Anthony A. Rayner
, Stephen E. Ettinghausen
, John T. Vetto
, Claudia A. Seipp
, Steven A. Rosenberg
Research output
:
Contribution to journal
›
Article
›
peer-review
285
!!Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Clinical effects and toxicity of interleukin‐2 in patients with cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Adoptive Transfer
33%
AIDS/HIV
33%
Clinical Effect
100%
Clinical Parameters
33%
Clinical Toxicity
100%
Cumulative Dose
33%
Eosinophilia
33%
Glycoprotein
33%
Hematotoxicity
33%
Hepatic Toxicity
33%
High Dose
33%
Immune Response
33%
Immunological Status
33%
Jurkat
66%
Lung
33%
Malaise
33%
Malignancy
33%
Maximum Tolerated Dose
33%
Melanoma
33%
Mild Anaemia
33%
Murine Tumor Model
33%
Natural Killer Cells
33%
Partial Response
33%
Patients with Cancer
100%
Recombinant
66%
Recombinant Escherichia Coli
33%
Renal Toxicity
33%
Single Bolus
33%
Solid Tumors
33%
T Cells
66%
Thrombocytopenia
33%
Tumor
33%
Weight Gain
100%
Nursing and Health Professions
Acquired Immune Deficiency Syndrome
100%
Adoptive Transfer
100%
Anemia
100%
Drug Megadose
100%
Eosinophilia
100%
Glycoprotein
100%
Malaise
100%
Maximum Permissible Dose
100%
Metastatic Melanoma
100%
Neoplasm
100%
Solid Malignant Neoplasm
100%
Thrombocytopenia
100%
Tumor Model
100%
Pharmacology, Toxicology and Pharmaceutical Science
Acquired Immune Deficiency Syndrome
50%
Anemia
50%
Eosinophilia
50%
Escherichia coli
50%
Glycoprotein
50%
Hepatic Toxicity
50%
Malaise
50%
Malignant Neoplasm
100%
Metastatic Melanoma
50%
Murine
50%
Neoplasm
50%
Nephrotoxicity
50%
Recombinant
100%
Solid Malignant Neoplasm
50%
Thrombocytopenia
50%
Tumor Model
50%